The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO)

Author:

Speranza Desirèe1,Sapuppo Elena1,Aprile Giuseppe2,Auriemma Alessandra3,Bergamo Francesca4ORCID,Bianco Roberto5,Bordonaro Roberto6,Brandi Giovanni78,Brunetti Oronzo9,Carnaghi Carlo10,Ciliberto Domenico11,Cinieri Saverio12,Corallo Salvatore13ORCID,De Vita Ferdinando14,Di Donato Samantha15,Ferraù Francesco16,Fornaro Lorenzo17,Barucca Viola18,Giommoni Elisa19,Lotesoriere Claudio20ORCID,Luchini Claudio21,Masini Cristina22,Niger Monica23,Pisconti Salvatore24,Rapposelli Ilario Giovanni25ORCID,Rimassa Lorenza2627,Rognone Chiara28,Rodriquenz Maria Grazia29,Corsini Lidia Rita30,Santin Daniele31,Scarpa Aldo21,Scartozzi Mario32,Soto Parra Hector33,Tonini Giuseppe3435,Tortora Giampaolo3637,Tralongo Paolo38,Silvestris Nicola1ORCID

Affiliation:

1. Medical Oncology Unit, Department of Human Pathology G. Barresi, University of Messina, Messina, Sicily, Italy

2. Department of Oncology, San Bortolo General Hospital, ULSS 8 Berica-Vicenza, Vicenza, Veneto, Italy

3. Medical Oncology Section, Department of Medicine, University of Verona, Verona, Veneto, Italy

4. Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Veneto, Italy

5. Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Campania, Italy

6. Medical Oncology Unit, ARNAS Garibaldi, Catania, Sicily, Italy

7. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Emilia-Romagna, Italy

8. Alma Mater Studiorum - University of Bologna - Department of Medical and Surgical Sciences, Bologna, Emilia-Romagna, Italy

9. Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Apulia, Italy

10. Clinical Trials Unit, Istituto Clinico Humanitas, Centro Catanese di Oncologia, Catania, Sicily, Italy

11. University Magna Græcia of Catanzaro, Catanzaro, Calabria, Italy

12. Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Apulia, Italy

13. Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy

14. Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania Luigi Vanvitelli, Naples, Campania, Italy

15. Medical Oncology Department ASL Toscana Centro, Santo Stefano Hospital Prato

16. St. Vincent Hospital, Division of Medical Oncology, Taormina, Messina, Sicily, Italy

17. Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Tuscany, Italy

18. UOC Oncologia, Azienda Ospedaliera San Camillo- Forlanini, Roma, Lazio, Italy

19. Medical Oncology Unit, Careggi University Hospital, Florence, Tuscany, Italy

20. Oncology Unit of National Institute of Gastroenterology - IRCCS Saverio de Bellis, Research Hospital Castellana Grotte, Bari, Apulia, Italy

21. Department of Diagnostics and Public Health, Section of Pathology, and ARC-Net Research Center, University and Hospital Trust of Verona, Verona, Veneto, Italy

22. Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy

23. Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardy, Italy

24. Unit of Medical Oncology, Ospedale S.G. Moscati, Taranto, Apulia, Italy

25. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Emilia-Romagna, Italy

26. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Lombardy, Italy

27. Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Lombardy, Italy

28. Department of Oncology, University of Turin, AO Ordine Mauriziano Hospital, Turin, Italy

29. Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

30. Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Sicily, Italy

31. Oncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, Lazio, Italy

32. Medical Oncology, University and University Hospital, Cagliari, Sardinia, Italy

33. Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Sicily, Italy

34. Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Lazio, Italy

35. Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Lazio, Italy

36. Medical Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy

37. Università Cattolica del Sacro Cuore, Rome, Lazio, Italy

38. Medical Oncology Unit, Medical Oncology Department, Umberto I Hospital, RAO, Siracusa, Sicily, Italy

Abstract

Introduction: About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization, and sensitivity to the various possible therapies, including molecular-based treatments. Such rare tumors are described only in case reports or small retrospective series because of their exclusion from clinical trials. This national initiative, here presented, aims to address the following knowledge gap: a) how much does histological diversity translate into clinical manifestation variety? b) are those chemotherapy regimens, recommended for conventional biliary tract cancers, potentially active in rare variants? Therefore, epidemiological, pathological, and clinical characterization of series of rare biliary histotypes/variants, for which therapeutic and follow-up data are available, will be collected. Methods: An Italian task force on rare tumors of the biliary tract (IRaBiCa) has been created, whose initiative is a multicenter retrospective study involving 34 Italian cancer centers. Clinical data from approximately 100 patients will be collected and analyzed. Continuous variables will be presented as median ± standard deviation, while categorical variables will be expressed in terms of frequency. Kaplan-Maier analyses will be used to compare disease free, progression free and overall survival, according to the different histotypes. Conclusions: We expect to gather novel data on rare histotypes of biliary tract cancer that will be useful to support their molecular and immunological characterization.

Publisher

SAGE Publications

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3